Pain News and Research

Latest Pain News and Research

Sex enhancement product recalled after Health Canada test finds undeclared drug ingredient

One lot of the sex enhancement product "Forta for Men" (NPN 80045132) is being recalled after Health Canada testing confirmed it contains an undeclared drug: homosildenafil.

31 Dec 2014

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

31 Dec 2014

AVACEN Medical launches $2M campaign in response to positive outcomes of fibromyalgia study

AVACEN Medical announced today that it has launched a $2 million campaign on Crowdfunder.com to support further company clinical trials and FDA applications.

31 Dec 2014

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic.

30 Dec 2014

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.

29 Dec 2014

Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA.

29 Dec 2014

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Based on its recent analysis of the influenza vaccines market, Frost & Sullivan recognises Protein Sciences with the 2013 Global New Product Innovation Award. Flublok is the world's first recombinant protein vaccine for the prevention of seasonal influenza disease to gain U.S. FDA approval.

29 Dec 2014

Top notch endodontic care for patients with dental anxiety

It's no secret that vast majority of Americans don't look forward to a visit to the dentist. According to the American Association of Endodontists, a striking 80% of US adults experience dental fear or anxiety. On some levels, fear of the dentist is understandable because a checkup or a procedure involves poking and prodding around the mouth of a patient with an intimidating looking set of tools.

29 Dec 2014

Better dental treatment needed for healthy mouth

Receiving treatment from a warm, friendly, and compassionate medical specialist is important in any field of medicine. In the field of dentistry, however, it's absolutely essential. A huge percentage of the population experiences fear or anxiety when it comes to the dentist.

27 Dec 2014

Three common health problems tied to oral health

Many people think that going to the dentist is all about getting a bright and shining smile. While this is an important aspect of dentistry, an experienced dentist like Farzad Feiz, DDS, of Calabasas Dental Group and California Dental Care can also help patients with their overall health.

27 Dec 2014

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

United Therapeutics Corporation (NASDAQ: UTHR) announced today that Medtronic, Inc. (NYSE: MDT) has submitted a pre-market approval application to the U.S. Food and Drug Administration (FDA) for the use of Medtronic's SynchroMed® II implantable drug infusion system (including a newly developed catheter) for use with United Therapeutics' Remodulin® (treprostinil) Injection delivered intravenously to patients with pulmonary arterial hypertension.

25 Dec 2014

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management.

25 Dec 2014

Using laparoscopy for VP shunt placement can decrease rate of distal shunt failures

Researchers conducted a prospective randomized controlled clinical trial at Bern University Hospital in Switzerland to compare a laparoscopic procedure with a mini-laparotomy for insertion of a peritoneal catheter during ventriculoperitoneal (VP) shunt surgery. The deciding factor was the rate of shunt malfunction.

23 Dec 2014

Medical researchers at Saint Louis University bring hope to those in pain and sickness

This year, Saint Louis University medical researchers advanced their fields, contributing to human knowledge and bringing hope to those in pain and sickness.

23 Dec 2014

Injection technique provides pain relief following knee replacement surgery

It's estimated that more than half of adults in the United States diagnosed with knee osteoarthritis will undergo knee replacement surgery.

22 Dec 2014

Bilateral shoulder-level amputee controls APL's Modular Prosthetic Limbs

A Colorado man made history at the Johns Hopkins University Applied Physics Laboratory (APL) this summer when he became the first bilateral shoulder-level amputee to wear and simultaneously control two of the Laboratory's Modular Prosthetic Limbs.

22 Dec 2014

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration approved the intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.

19 Dec 2014

Gene variations predispose mestizo Mexican population to develop severe form of COPD

A study by Ramcés Falfán-Valencia, researcher at the National Institute of Respiratory Diseases, found that the mestizo Mexican population has a number of variations in certain genes that predispose them to develop the most severe form of chronic obstructive pulmonary disease (COPD).

19 Dec 2014

Certain complementary medicines may cause side effects, warns NPS MedicineWise

With new information from Melbourne’s Peter MacCallum Cancer Centre revealing that some complementary medicines can interact with cancer treatment, NPS MedicineWise reminds all Australians that complementary medicines can cause side effects, and interact with other over-the-counter and prescription medicines.

19 Dec 2014

$Nuvo Research completes WF10 Phase 2 trial in patients with refractory allergic rhinitis$

Nuvo Research completes WF10 Phase 2 trial in patients with refractory allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of immunology and topical products, today announced that 179 patients have completed its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial to investigate the safety and efficacy of WF10 in patients with refractory allergic rhinitis.

18 Dec 2014

Pain News and Research

Latest Pain News and Research

Sex enhancement product recalled after Health Canada test finds undeclared drug ingredient

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

AVACEN Medical launches $2M campaign in response to positive outcomes of fibromyalgia study

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Newron, Zambon announce re-submission of safinamide NDA to FDA

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Top notch endodontic care for patients with dental anxiety

Better dental treatment needed for healthy mouth

Three common health problems tied to oral health

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Using laparoscopy for VP shunt placement can decrease rate of distal shunt failures

Medical researchers at Saint Louis University bring hope to those in pain and sickness

Injection technique provides pain relief following knee replacement surgery

Bilateral shoulder-level amputee controls APL's Modular Prosthetic Limbs

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Gene variations predispose mestizo Mexican population to develop severe form of COPD

Certain complementary medicines may cause side effects, warns NPS MedicineWise

Nuvo Research completes WF10 Phase 2 trial in patients with refractory allergic rhinitis

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Pain News and Research

Latest Pain News and Research

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in